Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS-001 (Pyridostigmine + Ondansetron) in Myasthenia Gravis
NCT04226170Phase 2Terminated
- Sponsor
- DAS-MG, Inc.
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ondansetron + pyridostigmine in myasthenia gravis (MG) (2 arms), sponsored by DAS-MG, Inc. Primary endpoint: Number of participants with change in the gastrointestinal (GI) side effects at 6 weeks. Started Nov 2023; status: terminated.
02
Drugs
ondansetron + pyridostigmine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04226170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226170.